{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:29:08Z","timestamp":1769005748029,"version":"3.49.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Directorate Industrial Research Project","award":["W2207-08ES02\/001\/SV"],"award-info":[{"award-number":["W2207-08ES02\/001\/SV"]}]},{"name":"DGSTO","award":["14fe05"],"award-info":[{"award-number":["14fe05"]}]},{"name":"Agility Funds, and Defence Research and Development Canada Applied Research","award":["WBE 14fe04"],"award-info":[{"award-number":["WBE 14fe04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Mesenchymal stromal cells (MSCs) are being exploited as gene delivery vectors for various disease and injury therapies. We provide proof-of-concept that engineered MSCs can provide a useful, effective platform for protection against infectious disease. Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne pathogen affecting humans and equines and can be used in bio-warfare. No licensed vaccine or antiviral agent currently exists to combat VEEV infection in humans. Direct antibody administration (passive immunity) is an effective, but short-lived, method of providing immediate protection against a pathogen. We compared the protective efficacy of human umbilical cord perivascular cells (HUCPVCs; a rich source of MSCs), engineered with a transgene encoding a humanized VEEV-neutralizing antibody (anti-VEEV), to the purified antibody. In athymic mice, the anti-VEEV antibody had a half-life of 3.7 days, limiting protection to 2 or 3 days after administration. In contrast, engineered HUCPVCs generated protective anti-VEEV serum titers for 21\u201338 days after a single intramuscular injection. At 109 days after transplantation, 10% of the mice still had circulating anti-VEEV antibody. The mice were protected against exposure to a lethal dose of VEEV by an intramuscular pretreatment injection with engineered HUCPVCs 24 hours or 10 days before exposure, demonstrating both rapid and prolonged immune protection. The present study is the first to describe engineered MSCs as gene delivery vehicles for passive immunity and supports their utility as antibody delivery vehicles for improved, single-dose prophylaxis against endemic and intentionally disseminated pathogens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Direct injection of monoclonal antibodies (mAbs) is an important strategy to immediately protect the recipient from a pathogen. This strategy is critical during natural outbreaks or after the intentional release of bio-weapons. Vaccines require weeks to become effective, which is not practical for first responders immediately deployed to an infected region. However, mAb recipients often require booster shots to maintain protection, which is expensive and impractical once the first responders have been deployed. The present study has shown, for the first time, that mesenchymal stromal cells are effective gene delivery vehicles that can significantly improve mAb-mediated immune protection in a single, intramuscular dose of engineered cells. Such a cell-based delivery system can provide extended life-saving protection in the event of exposure to biological threats using a more practical, single-dose regimen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5966\/sctm.2015-0341","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T14:18:19Z","timestamp":1466691499000},"page":"1026-1035","source":"Crossref","is-referenced-by-count":16,"title":["Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure"],"prefix":"10.1093","volume":"5","author":[{"given":"Lorena R.","family":"Braid","sequence":"first","affiliation":[{"name":"Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada"},{"name":"Aurora BioSolutions Inc., Medicine Hat, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Gang","family":"Hu","sequence":"additional","affiliation":[{"name":"Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Biomaterials and Bioengineering, University of Toronto, Toronto, Ontario, Canada"},{"name":"Tissue Regeneration Therapeutics, Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les P.","family":"Nagata","sequence":"additional","affiliation":[{"name":"Bio-Threat Defence Section, Defence Research and Development Canada, Suffield Research Centre, Ralston, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"key":"2021122705032394000_R1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1634\/stemcells.2007-0197","article-title":"Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing","volume":"25","author":"Chamberlain","year":"2007","journal-title":"Stem Cells"},{"key":"2021122705032394000_R2","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","article-title":"Immunomodulatory properties of mesenchymal stromal cells","volume":"110","author":"Nauta","year":"2007","journal-title":"Blood"},{"key":"2021122705032394000_R3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5966\/sctm.2011-0012","article-title":"Concise review: Immunomodulatory properties of mesenchymal stem cells in cellular transplantation: Update, controversies, and unknowns","volume":"1","author":"Atoui","year":"2012","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122705032394000_R4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11373-004-8183-7","article-title":"T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression","volume":"12","author":"Klyushnenkova","year":"2005","journal-title":"J Biomed Sci"},{"key":"2021122705032394000_R5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","article-title":"Human mesenchymal stem cells modulate allogeneic immune cell responses","volume":"105","author":"Aggarwal","year":"2005","journal-title":"Blood"},{"key":"2021122705032394000_R6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1089\/hum.2010.165","article-title":"Genetic engineering of mesenchymal stem cells and its application in human disease therapy","volume":"21","author":"Hodgkinson","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2021122705032394000_R7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/gt.2008.35","article-title":"Therapeutic potential of genetically modified mesenchymal stem cells","volume":"15","author":"Kumar","year":"2008","journal-title":"Gene Ther"},{"key":"2021122705032394000_R8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/mp300261e","article-title":"Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin's lymphoma","volume":"10","author":"Yan","year":"2013","journal-title":"Mol Pharm"},{"key":"2021122705032394000_R9","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/stem.513","article-title":"Concise review: Stem cells as an emerging platform for antibody therapy of cancer","volume":"28","author":"Frank","year":"2010","journal-title":"Stem Cells"},{"key":"2021122705032394000_R10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1634\/stemcells.2008-0831","article-title":"Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds","volume":"27","author":"Compte","year":"2009","journal-title":"Stem Cells"},{"key":"2021122705032394000_R11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/nm912","article-title":"Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts","volume":"9","author":"Mangi","year":"2003","journal-title":"Nat Med"},{"key":"2021122705032394000_R12","doi-asserted-by":"crossref","first-page":"e9750","DOI":"10.1371\/journal.pone.0009750","article-title":"Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma","volume":"5","author":"Balyasnikova","year":"2010","journal-title":"PLoS One"},{"key":"2021122705032394000_R13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/term.228","article-title":"Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface","volume":"4","author":"Balyasnikova","year":"2010","journal-title":"J Tissue Eng Regen Med"},{"key":"2021122705032394000_R14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/14737175.2014.917964","article-title":"Therapeutic cell carriers: A potential road to cure glioma","volume":"14","author":"Young","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"2021122705032394000_R15","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/ijms15021719","article-title":"Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases","volume":"15","author":"Wyse","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2021122705032394000_R16","first-page":"197","article-title":"Human mesenchymal stem cells overexpressing therapeutic genes: From basic science to clinical applications for articular cartilage repair","volume":"22","author":"Cucchiarini","year":"2012","journal-title":"Biomed Mater Eng"},{"key":"2021122705032394000_R17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5966\/sctm.2012-0135","article-title":"Comparison of drug and cell-based delivery: Engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models","volume":"2","author":"Liu","year":"2013","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122705032394000_R18","first-page":"321","article-title":"Comparison of drug and cell-based delivery\u2014Engineering adult mesenchymal cells to deliver human erythropoietin","volume":"13","author":"Wang","year":"2009","journal-title":"Gene Ther Mol Biol"},{"key":"2021122705032394000_R19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4161\/hv.4.1.4778","article-title":"Antibody gene-based prophylaxis and therapy for biodefence","volume":"4","author":"Hu","year":"2008","journal-title":"Hum Vaccin"},{"key":"2021122705032394000_R20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2217\/fvl.13.42","article-title":"Vaccines and therapeutics for the encephalitic alphaviruses","volume":"8","author":"Nagata","year":"2013","journal-title":"Future Virol"},{"key":"2021122705032394000_R21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/cgt.2008.68","article-title":"Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV","volume":"16","author":"Ho","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"2021122705032394000_R22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/jgm.1100","article-title":"Gene therapy clinical trials worldwide to 2007\u2014An update","volume":"9","author":"Edelstein","year":"2007","journal-title":"J Gene Med"},{"key":"2021122705032394000_R23","volume-title":"Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee","author":"Committee on the Independent Review and Assessment of the Activities of the NIH Recombinant DNA Advisory Committee; Board on Health Sciences Policy; Institute of Medicine","year":"2014"},{"key":"2021122705032394000_R24","doi-asserted-by":"crossref","first-page":"e1004717","DOI":"10.1371\/journal.ppat.1004717","article-title":"The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases","volume":"11","author":"Casadevall","year":"2015","journal-title":"PLoS Pathog"},{"key":"2021122705032394000_R25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/CMR.00014-15","article-title":"Backs against the wall: Novel and existing strategies used during the 2014-2015 Ebola virus outbreak","volume":"28","author":"Wong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2021122705032394000_R26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1634\/stemcells.2004-0166","article-title":"Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors","volume":"23","author":"Sarugaser","year":"2005","journal-title":"Stem Cells"},{"key":"2021122705032394000_R27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/14653240801891667","article-title":"In vitro immunologic properties of human umbilical cord perivascular cells","volume":"10","author":"Ennis","year":"2008","journal-title":"Cytotherapy"},{"key":"2021122705032394000_R28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0091-679X(08)00007-1","article-title":"Isolation, characterization, and differentiation of human umbilical cord perivascular cells (HUCPVCs)","volume":"86","author":"Ennis","year":"2008","journal-title":"Methods Cell Biol"},{"key":"2021122705032394000_R29","doi-asserted-by":"crossref","first-page":"789526","DOI":"10.1155\/2009\/789526","article-title":"High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue","volume":"2009","author":"Schugar","year":"2009","journal-title":"J Biomed Biotechnol"},{"key":"2021122705032394000_R30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.placenta.2010.11.003","article-title":"Human umbilical cord stromal stem cell express CD10 and exert contractile properties","volume":"32","author":"Farias","year":"2011","journal-title":"Placenta"},{"key":"2021122705032394000_R31","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1634\/stemcells.2006-0709","article-title":"Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow","volume":"25","author":"Baksh","year":"2007","journal-title":"Stem Cells"},{"key":"2021122705032394000_R32","article-title":"Characterization of Genetically Modified HUCPVCs as an Osteogeneic Cell Source","author":"Vallejo","year":"2013"},{"key":"2021122705032394000_R33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu Rev Entomol"},{"key":"2021122705032394000_R34","doi-asserted-by":"crossref","first-page":"e1875","DOI":"10.1371\/journal.pntd.0001875","article-title":"Venezuelan equine encephalitis virus activity in the Gulf Coast region of Mexico, 2003-2010","volume":"6","author":"Adams","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2021122705032394000_R35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0022-510X(81)90030-7","article-title":"Central nervous system demyelination in Venezuelan equine encephalomyelitis infection","volume":"49","author":"Dal Canto","year":"1981","journal-title":"J Neurol Sci"},{"key":"2021122705032394000_R36","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1086\/513978","article-title":"Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995","volume":"175","author":"Rivas","year":"1997","journal-title":"J Infect Dis"},{"key":"2021122705032394000_R37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0300985810372508","article-title":"Review paper: Pathology of animal models of alphavirus encephalitis","volume":"47","author":"Steele","year":"2010","journal-title":"Vet Pathol"},{"key":"2021122705032394000_R38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.micro.55.1.235","article-title":"Biological weapons\u2014A primer for microbiologists","volume":"55","author":"Hawley","year":"2001","journal-title":"Annu Rev Microbiol"},{"key":"2021122705032394000_R39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"2021122705032394000_R40","first-page":"1","article-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy\u201448th Annual Meeting and Infectious Diseases Society of America\u201446th Annual Meeting Updates on therapeutic research\u2014Part 1","volume":"12","author":"Gale","year":"2009","journal-title":"IDrugs"},{"key":"2021122705032394000_R41","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.vaccine.2008.04.044","article-title":"Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates","volume":"26","author":"Fine","year":"2008","journal-title":"Vaccine"},{"key":"2021122705032394000_R42","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"key":"2021122705032394000_R43","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: Testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"key":"2021122705032394000_R44","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.vaccine.2007.01.034","article-title":"Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"key":"2021122705032394000_R45","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/j.vaccine.2010.06.038","article-title":"A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus","volume":"28","author":"Hu","year":"2010","journal-title":"Vaccine"},{"key":"2021122705032394000_R46","doi-asserted-by":"crossref","first-page":"e42662","DOI":"10.1371\/journal.pone.0042662","article-title":"Adenoviral transduction of mesenchymal stem cells: In vitro responses and in vivo immune responses after cell transplantation","volume":"7","author":"Treacy","year":"2012","journal-title":"PLoS One"},{"key":"2021122705032394000_R47","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtcvs.2003.07.037","article-title":"Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium","volume":"127","author":"Grinnemo","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2021122705032394000_R48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/jcm.4.1.61-66.1976","article-title":"Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells","volume":"4","author":"Schmidt","year":"1976","journal-title":"J Clin Microbiol"},{"key":"2021122705032394000_R49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"2021122705032394000_R50","doi-asserted-by":"crossref","first-page":"207ra143","DOI":"10.1126\/scitranslmed.3006605","article-title":"mAbs and Ad-vectored IFN-\u03b1 therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms","volume":"5","author":"Qiu","year":"2013","journal-title":"Sci Transl Med"},{"key":"2021122705032394000_R51","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1128\/JVI.00173-13","article-title":"Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs","volume":"87","author":"Qiu","year":"2013","journal-title":"J Virol"},{"issue":"suppl","key":"2021122705032394000_R52","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2404::AID-CNCR11>3.0.CO;2-G","article-title":"Endogenous anti-tumor antibody responses in nude mice","volume":"80","author":"Stigbrand","year":"1997","journal-title":"Cancer"},{"key":"2021122705032394000_R53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"2021122705032394000_R54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1089\/10430340152480258","article-title":"Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo","volume":"12","author":"Bartholomew","year":"2001","journal-title":"Hum Gene Ther"},{"key":"2021122705032394000_R55","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","journal-title":"Pediatrics"},{"key":"2021122705032394000_R56","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0301-472X(00)00134-X","article-title":"Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells","volume":"28","author":"Conget","year":"2000","journal-title":"Exp Hematol"},{"key":"2021122705032394000_R57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1525-0016(02)00062-X","article-title":"Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector","volume":"7","author":"Tsuda","year":"2003","journal-title":"Mol Ther"},{"key":"2021122705032394000_R58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/scd.2007.0201","article-title":"Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging","volume":"17","author":"Vilalta","year":"2008","journal-title":"Stem Cells Dev"},{"key":"2021122705032394000_R59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/jor.22282","article-title":"In vivo bioluminescence imaging of magnetically targeted bone marrow-derived mesenchymal stem cells in skeletal muscle injury model","volume":"31","author":"Nakabayashi","year":"2013","journal-title":"J Orthop Res"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0341","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5966\/sctm.2015-0341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5966\/sctm.2015-0341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/8\/1026\/41877092\/stcltm_5_8_1026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/5\/8\/1026\/41877092\/stcltm_5_8_1026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:50:46Z","timestamp":1642560646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/5\/8\/1026-1035\/6397603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,6,22]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2015-0341","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,8,1]]},"published":{"date-parts":[[2016,6,22]]}}}